SEC Form 4 filed by Broadrick Dale

$BRTX
Managed Health Care
Health Care
Get the next $BRTX alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Broadrick Dale

(Last) (First) (Middle)
3003 BRICK CHURCH PIKE

(Street)
NASHVILLE TN 37207

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BioRestorative Therapies, Inc. [ BRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/27/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/27/2023 P 1,000 A $2.8(1) 306,073(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to acquire Common Stock $120 02/19/2019 02/19/2024 Common Stock 250 250 D
Warrant to acquire Common Stock $120 05/07/2019 05/07/2024 Common Stock 276 276 D
Warrant to acquire Common Stock $120 10/16/2019 10/16/2024 Common Stock 833 833 D
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $2.75 to $2.85 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
2. The reporting person also owns 316,972 shares indirectly through Fleetco, Inc. of which the reporting person is a 93% shareholder.
/s/ Dale Broadrick 07/27/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $BRTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BRTX

DatePrice TargetRatingAnalyst
12/1/2021$37.00Buy
Roth Capital
More analyst ratings

$BRTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

    MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern time. Benzinga All-Access Show Date: Tuesday, April 15, 2025Time: 10:50 a.m. Eastern TimeLive Webcast: https://youtube.com/live/YVur35nB9nc?feature=share The interview will also be archived on the Investors section of the Company's website. About BioRestorative Therapies

    $BRTX
    Managed Health Care
    Health Care
  • BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

    MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to confirm that it currently faces no material exposure to newly imposed U.S. tariffs. BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is BioRestorative's lead clinical candidate. The safety and efficacy of BRTX-100 in treating chronic lumbar disc disease ("cLDD") is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. The U.S. Food and Drug A

    $BRTX
    Managed Health Care
    Health Care
  • BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

    MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business. "2024 was a transformative year for BioRestorative, highlighted by significantly improved financial performance and meaningful clinical program advancement," said Lance Alstodt, BioRestorative's Chief Executive Officer. "Looking ahead, we remain focused on aggressively executing our growth strategy, and very much look forward to updating investors as we progr

    $BRTX
    Managed Health Care
    Health Care

$BRTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BRTX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BRTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BRTX
SEC Filings

See more

$BRTX
Leadership Updates

Live Leadership Updates

See more
  • BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance

    MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease. Mr. Paccasassi has over 25 years of biotech operations and combined experience in Quality Assurance, Regulatory Compliance, and Manufacturing. Prior to joining BioRestorative, Mr. Paccasassi

    $BRTX
    Managed Health Care
    Health Care
  • BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer

    MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which

    $BRTX
    Managed Health Care
    Health Care

$BRTX
Financials

Live finance-specific insights

See more
  • BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

    MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business. "2024 was a transformative year for BioRestorative, highlighted by significantly improved financial performance and meaningful clinical program advancement," said Lance Alstodt, BioRestorative's Chief Executive Officer. "Looking ahead, we remain focused on aggressively executing our growth strategy, and very much look forward to updating investors as we progr

    $BRTX
    Managed Health Care
    Health Care
  • BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025

    MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its 2024 financial results after market close on Thursday, March 27, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. 2024 Results Conference Call Details: Date:Thursday, March 27, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:726526 The call will also be broadcast live and arch

    $BRTX
    Managed Health Care
    Health Care
  • BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

    – BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company's advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain – – Company to host webcasted conference call today at 10:30am EST – MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application f

    $BRTX
    Managed Health Care
    Health Care

$BRTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more